Patent ID: 9556281
Date: 2017-01-31
CPC Classifications: A61J,A61K,A61P,C07K,G01N

Claim:
1. A method of treating or inhibiting Staphylococcus aureus infection in a patient comprising administering to said patient an effective amount of a purified Staphylococcal protein A (SpA) binding polypeptide that specifically binds at least two SpA IgG binding domains A, B, C, D and E of a SpA variant that lacks non-specific Ig-binding activity, wherein the binding polypeptide comprises CDR1, CDR2 and CDR3 of both the light and heavy chains of a 5A10 monoclonal antibody (SEQ ID NO: 16-18, 11-13, respectively), 8E2 monoclonal antibody (SEQ ID NO: 26-28, 21-23, respectively), 3F6 monoclonal antibody (SEQ ID NO: 56-58, 51-53, respectively), 1F10 monoclonal antibody (SEQ ID NO: 66-68, 61-63, respectively), 3D11 monoclonal antibody (SEQ ID NO: 86-88, 81- 83, respectively) or 2F2 monoclonal antibody (SEQ ID NO: 101-103, 96-98, respectively), wherein each of CDR1 CDR2 and CDR3 have up to one amino acid substitution.